Details of the Drug

General Information of Drug (ID: DMTKZ1Q)

Drug Name
DS-6157
Indication
Disease Entry ICD 11 Status REF
Gastrointestinal stromal tumour 2B5B Phase 1 [1]
Drug Type
Antibody drug conjugate
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 312.93
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
Chemical Identifiers
Formula
C7H6BrIO
IUPAC Name
4-bromo-2-iodo-1-methoxybenzene
Canonical SMILES
COC1=C(C=C(C=C1)Br)I
InChI
InChI=1S/C7H6BrIO/c1-10-7-3-2-5(8)4-6(7)9/h2-4H,1H3
InChIKey
CTPNHFOXNXLPCW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
10979904
TTD ID
DJ4X7D

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase I (TOP1) TTGTQHC TOP1_HUMAN Inhibitor [2]
G-protein coupled receptor 20 (GPR20) TT26C7Z GPR20_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Gastrointestinal stromal tumour
ICD Disease Classification 2B5B
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
DNA topoisomerase I (TOP1) DTT TOP1 6.65E-01 0.2 0.39
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04276415) DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST). U.S. National Institutes of Health.
2 Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523.